Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAK1 | Q13153 | 4/20 | 0.70 |
| ▸ | PKN1 | Q16512 | 4/20 | 0.70 |
| ▸ | PAK3 | O75914 | 3/20 | 0.70 |
| ▸ | PAK2 | Q13177 | 3/20 | 0.70 |
| ▸ | PAK4 | O96013 | 3/20 | 0.70 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.70 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.70 |
| ▸ | WEE1 | P30291 | 1/20 | 0.59 |
| ▸ | TNK2 | Q07912 | 11/20 | 0.57 |
| ▸ | AXL | P30530 | 1/20 | 0.53 |
| ▸ | EGFR | P00533 | 1/20 | 0.52 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.52 |
| ▸ | SRC | P12931 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15035162 | 0.94 | PAK1 (0.70) | PAK1PKN1PAK3PAK2PAK4 | |
| SCHEMBL15035160 | 0.94 | PAK1 (0.67) | PAK1PKN1PAK3PAK2PAK4 | |
| SCHEMBL14824793 | 0.94 | PAK1 (0.67) | PAK1PKN1PAK3PAK2PAK4 | |
| SCHEMBL15035165 | 0.92 | PAK1 (0.67) | PAK1PKN1PAK3PAK2PAK4 | |
| SCHEMBL14824794 | 0.92 | PAK1 (0.69) | PAK1PKN1PAK3PAK2PAK4 | |
| SCHEMBL15035147 | 0.92 | PAK1 (0.82) | PAK1PKN1PAK3PAK2PAK4 | |
| SCHEMBL15041505 | 0.91 | PAK1 (0.67) | PAK1PKN1PAK3PAK2PAK4 | |
| SCHEMBL13553595 | 0.89 | PAK1 (0.81) | PAK1PKN1PAK3PAK2PAK4 | |
| SCHEMBL14824806 | 0.89 | PAK1 (0.81) | PAK1PKN1PAK3PAK2PAK4 | |
| SCHEMBL14824760 | 0.88 | PAK1 (0.67) | PAK1PKN1PAK3PAK2PAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | AFRAXIS, INC. (US) | 2013-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | PAK5, PAK2, PAK6 | PAK1 4/4885PKN1 326/4885PAK3 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.